GlassScriptPhysician profile
Sunny Green
NPI 1649543752
$3,856.54
in general payments reported to CMS, 2019-2025
28 companies · $865 in 2025
The $865 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $876 · 2022: $923 · 2023: $618 · 2024: $575 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.32 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.67 | 2021-2025 | |
| Astellas Pharma US INC | $432.12 | 2023-2025 | Veozah |
| Abbott Laboratories | $418.96 | 2022-2025 | Freestyle Libre 3, Eterna, Freestyle Libre |
| Novo Nordisk INC | $368.64 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $324.66 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $292.45 | 2021-2022 | |
| Heron Therapeutics, INC. | $232.76 | 2025 | Zynrelef, Aponvie |
| Daiichi Sankyo INC. | $159.52 | 2022-2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $132.24 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $94.34 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.75 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.79 | 2022 | |
| Antares Pharma, INC. | $58.12 | 2022-2025 | Xyosted |
| Amgen INC. | $55.65 | 2021-2022 | |
| Vbi Vaccine (Delaware) INC. | $51.54 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $45.33 | 2025 | Rexulti |
| Pfizer INC. | $43.51 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $35.36 | 2024 | Voquezna |
| Boston Scientific Corporation | $25.92 | 2025 | Watchman Flx |
| Exact Sciences Corporation | $24.37 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $23.79 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $22.28 | 2022 | |
| Halozyme INC | $19.18 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.70 | 2022 | |
| Shield Therapeutics INC | $14.05 | 2023 | Accrufer |
| Sunovion Pharmaceuticals INC. | $13.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.56 | 2021 | |
| Sumitomo Pharma America, INC. | $7.21 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunny Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.